SUBSCRIBE
SUBSCRIBE
News   Drug Development

Array BioPharma, Inc. Initiates Phase 1 Clinical Trial for MEK Inhibitor ARRY-300

January 9, 2009 | 
1 min read
BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) has initiated dosing in healthy volunteers in a Phase 1 clinical trial with ARRY-300, a targeted small molecule MEK inhibitor.
Clinical research Phase I
MORE ON THIS TOPIC
Targeting cancer as oncology drugs and oncologist symbol for preventing malignant tumor growth disease as a symbol for pharmaceutical science and immunology or fighting human cancers.
Cancer
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep
December 15, 2025
 · 
2 min read
 · 
Heather McKenzie
Illustration of businessman running back around
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hypnose eye with sharp lines. Focus illusion.
Autoimmune disease
Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration showing hurdles along a path ending in an arrow
Multiple sclerosis
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application
December 15, 2025
 · 
2 min read
 · 
Annalee Armstrong